Key business development activities during the quarter included the strengthening of our relationships
with State Governments for the supply of EuGeni tests once TGA approved and, importantly, the
renewal of the Ellume contract for the ongoing supply of AnteoBind for a further five years
Ann: Quarterly Update / Appendix 4C, page-7
-
- There are more pages in this discussion • 235 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ADO (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.2¢ |
Change
0.001(4.76%) |
Mkt cap ! $54.77M | |||
| Open | High | Low | Value | Volume |
| 2.0¢ | 2.2¢ | 2.0¢ | $12.70K | 583.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1191253 | 2.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.2¢ | 520012 | 3 |
View Market Depth
| Last trade - 16.10pm 01/10/2024 (20 minute delay) ? |
| ADO (ASX) Chart |